领航医药生物科技(00399.HK)拟出售精优药业19.14%股份及5.77亿港元可换股债
格隆汇6月24日丨领航医药生物科技(00399.HK)公告,于2019年6月23日,公司与公司的主要股东毛裕民博士(买方)订立一份买卖协议,据此,本公司有条件同意出售而买方有条件同意收购(i)精优药业控股有限公司(股份代号:00858)(目标公司)已发行股本中每股面值0.01港元的4.58亿股普通股及(ii)目标公司所发行本金额合共5.77亿港元的可换股债券,其具有换股权,可按代价0.6413港元(不计利息)转换为目标公司9亿股普通股,总代价为2.7亿港元。
待售股份相当于目标公司已发行股本约19.14%,目标公司为本公司的联营公司,其财务业绩并无并入本公司的业绩内。紧随出售事项后,本公司将不再持有目标公司任何股份及可换股债券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.